Cover Image
市場調查報告書

伊波拉/馬爾堡出血熱開發中產品分析

Ebola and Marburg Infections - Pipeline Review, H1 2014

出版商 Global Markets Direct 商品編碼 271828
出版日期 內容資訊 英文 53 Pages
訂單完成後即時交付
價格
Back to Top
伊波拉/馬爾堡出血熱開發中產品分析 Ebola and Marburg Infections - Pipeline Review, H1 2014
出版日期: 2014年06月15日 內容資訊: 英文 53 Pages
簡介

伊波拉出血熱及馬爾堡出血熱二種都是病毒性感染症,特徵是出血及複數內臟功能不全。病毒藉由人與人直接接觸,或接觸感染動物之體液來傳染。主要的症狀為發燒和激烈的頭痛、腹瀉、胸部疼痛、咳嗽、關節痛·肌肉痛·發冷、喉嚨頭痛、倦怠感等。

本報告提供全球各國治療伊波拉病毒/馬爾堡病毒感染疾病(出血熱)治療用開發中產品的開發情形相關分析,產品開發·上市的最新趨勢,及臨床實驗各階段的產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

伊波拉病毒/馬爾堡病毒感染疾病概要

治療藥的開發

  • 伊波拉/馬爾堡出血熱開發中產品:概要
  • 伊波拉/馬爾堡出血熱開發中產品:比較分析

各企業開發中的伊波拉/馬爾堡出血熱治療藥

大學/研究機關研究中的伊波拉/馬爾堡出血熱治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

伊波拉/馬爾堡出血熱治療藥:開發中的產品一覽(各企業)

伊波拉/馬爾堡出血熱治療藥:研究中的產品一覽(大學/研究機關別)

伊波拉/馬爾堡出血熱治療藥的開發企業

  • GlaxoSmithKline plc
  • Inovio Pharmaceuticals, Inc.
  • Bavarian Nordic A/S
  • Crucell N.V.
  • NanoViricides, Inc.
  • AlphaVax, Inc.
  • Immunovaccine, Inc.
  • Integrated BioTherapeutics, Inc.
  • Profectus BioSciences, Inc.
  • Mapp Biopharmaceutical, Inc.

伊波拉/馬爾堡出血熱:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • Vaccine for Multivalent Filovirus
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • Ebola Vaccine + Marburg Vaccine
  • Vaccine For Filovirus
  • Ebola/Marburg Program
  • Ebola And Marburg Vaccine
  • Monoclonal Antibody for Marburg Virus
  • Polyvalent DNA Vaccine for Ebola and Marburg Filoviruses
  • MVA-BN-Filoviruses Vaccine
  • rVSV-Vectored Vaccines
  • Subunit Vaccine for Multifiloviruses
  • Monoclonal Antibodies to Inhibit Glycoprotein for Marburg Virus Infection
  • Monoclonal Antibodies for Ebola and Marburg Infections

伊波拉/馬爾堡出血熱治療藥:開發中產品的最新趨勢

伊波拉/馬爾堡出血熱治療藥:暫停開發的產品

伊波拉/馬爾堡出血熱治療藥:中止開發的產品

伊波拉/馬爾堡出血熱相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿(全10件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5120IDB

Global Markets Direct's, 'Ebola and Marburg Infections - Pipeline Review, H1 2014', provides an overview of the Ebola and Marburg Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ebola and Marburg Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Ebola and Marburg Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Ebola and Marburg Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Ebola and Marburg Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Ebola and Marburg Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Ebola and Marburg Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Ebola and Marburg Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Ebola and Marburg Infections Overview
  • Therapeutics Development
    • Pipeline Products for Ebola and Marburg Infections - Overview
    • Pipeline Products for Ebola and Marburg Infections - Comparative Analysis
  • Ebola and Marburg Infections - Therapeutics under Development by Companies
  • Ebola and Marburg Infections - Therapeutics under Investigation by Universities/Institutes
  • Ebola and Marburg Infections - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Ebola and Marburg Infections - Products under Development by Companies
  • Ebola and Marburg Infections - Products under Investigation by Universities/Institutes
  • Ebola and Marburg Infections - Companies Involved in Therapeutics Development
    • GlaxoSmithKline plc
    • Inovio Pharmaceuticals, Inc.
    • Bavarian Nordic A/S
    • Crucell N.V.
    • NanoViricides, Inc.
    • AlphaVax, Inc.
    • Immunovaccine, Inc.
    • Integrated BioTherapeutics, Inc.
    • Profectus BioSciences, Inc.
    • Mapp Biopharmaceutical, Inc.
  • Ebola and Marburg Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Vaccine for Multivalent Filovirus - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Ebola Vaccine + Marburg Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine For Filovirus - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Ebola/Marburg Program - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Ebola And Marburg Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Marburg Virus - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Polyvalent DNA Vaccine for Ebola and Marburg Filoviruses - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MVA-BN-Filoviruses Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rVSV-Vectored Vaccines - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Subunit Vaccine for Multifiloviruses - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit Glycoprotein for Marburg Virus Infection - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Ebola and Marburg Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Ebola and Marburg Infections - Recent Pipeline Updates
  • Ebola and Marburg Infections - Dormant Projects
  • Ebola and Marburg Infections - Discontinued Products
  • Ebola and Marburg Infections - Product Development Milestones
    • Featured News & Press Releases
      • Sep 18, 2012: Sarepta Therapeutics's Marburg Drug Receives FDA Fast Track Designation
      • Sep 04, 2012: Sarepta Therapeutics Receives $3.9m Contract From U.S. Government To Evaluate Feasibility Of Alternate Route Of Administration Of AVI-7288 For Treatment Of Marburg Virus
      • Jun 18, 2012: Bavarian Nordic Receives Contract From US Government To Advance Development Of New MVA-BN Based Vaccines
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Ebola and Marburg Infections, H1 2014
  • Number of Products under Development for Ebola and Marburg Infections - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Products under Investigation by Universities/Institutes, H1 2014
  • Ebola and Marburg Infections - Pipeline by GlaxoSmithKline plc, H1 2014
  • Ebola and Marburg Infections - Pipeline by Inovio Pharmaceuticals, Inc., H1 2014
  • Ebola and Marburg Infections - Pipeline by Bavarian Nordic A/S, H1 2014
  • Ebola and Marburg Infections - Pipeline by Crucell N.V., H1 2014
  • Ebola and Marburg Infections - Pipeline by NanoViricides, Inc., H1 2014
  • Ebola and Marburg Infections - Pipeline by AlphaVax, Inc., H1 2014
  • Ebola and Marburg Infections - Pipeline by Immunovaccine, Inc., H1 2014
  • Ebola and Marburg Infections - Pipeline by Integrated BioTherapeutics, Inc., H1 2014
  • Ebola and Marburg Infections - Pipeline by Profectus BioSciences, Inc., H1 2014
  • Ebola and Marburg Infections - Pipeline by Mapp Biopharmaceutical, Inc., H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Assessment by Combination Products, H1 2014
  • Number of Products by Stage and Target, H1 2014
  • Number of Products by Stage and Mechanism of Action, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Ebola and Marburg Infections Therapeutics - Recent Pipeline Updates, H1 2014
  • Ebola and Marburg Infections - Dormant Projects, H1 2014
  • Ebola and Marburg Infections - Discontinued Products, H1 2014

List of Figures

  • Number of Products under Development for Ebola and Marburg Infections, H1 2014
  • Number of Products under Development for Ebola and Marburg Infections - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Products, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Stage and Top 10 Target, H1 2014
  • Number of Products by Stage and Top 10 Route of Administration, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top